Drug Search Results
More Filters [+]

Reboxetine

Alternative Names: reboxetine, prolift, pnu-165442g, axs-12, axs12
Latest Update: 2024-02-14
Latest Update Note: News Article

Product Description

Pfizer is developing Reboxetine as a treatment for narcolepsy. (Sourced from: https://www.pfizer.com/news/press-release/press-release-detail/axsome-therapeutics-enters-exclusive-license-agreement)

Mechanisms of Action: NaR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral,Vaginal

FDA Designation: Breakthrough Therapy - Narcolepsy *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Chile | Croatia | Denmark | Egypt | Germany | Hungary | Iceland | India | Ireland | Israel | Italy | Luxembourg | New Zealand | Norway | Peru | Poland | Portugal | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Thailand | United Kingdom | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Reboxetine

Countries in Clinic: Canada, United States

Active Clinical Trial Count: 3

Highest Development Phases

Phase 3: Cataplexy|Disorders of Excessive Somnolence|Narcolepsy

Phase 2: Sleep Apnea, Obstructive

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

RENTOSA

P2

Not yet recruiting

Sleep Apnea, Obstructive

2024-12-01

AXS-12-302

P3

Enrolling by invitation

Disorders of Excessive Somnolence|Cataplexy|Narcolepsy

2024-12-01

90%

SYMPHONY

P3

Recruiting

Cataplexy|Narcolepsy|Disorders of Excessive Somnolence

2023-06-01

70%

Recent News Events